$18,326.97 consulting Payment -- Merck & Co to Dr. Paul Turner

Merck & Co. pays Infectious Disease specialist $18,326.97 for consulting services

This page provides a detailed analysis of a $18,326.97 consulting payment from Merck & Co to Dr. Paul Turner. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$18,326.97
Payment Typeconsulting
Payment NatureConsulting Fee
Pharmaceutical CompanyMerck & Co
PhysicianDr. Paul Turner
NPI Number1996786395
Physician SpecialtyInfectious Disease
LocationCity, VA
Date of Payment2025-04-16
Conflict AssessmentModerate -- Worth Noting

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Merck & Co made a $18.3K consulting payment to Paul Turner, a Infectious Disease specialist in City, VA. The payment of $18,326.97 to Dr. Paul Turner for consulting services from Merck & Co. is a significant amount for a single consulting engagement. The payment was made on April 16, 2025, indicating a recent engagement between the physician and the pharmaceutical company. The specialty of Infectious Disease is relevant, as pharmaceutical companies often seek expert consultation on new treatments and research in this area.

Patient Guidance: What This Payment Means for You

Patients should be aware that their doctors may receive payments from pharmaceutical companies for consulting, which helps advance medical knowledge. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Consulting fees for specialists can vary widely, but this amount is on the higher end for a single engagement, though not necessarily outside the norm for extensive or specialized consulting.

Regulatory Context: Sunshine Act Requirements

This payment falls under the Sunshine Act's reporting requirements for payments made by manufacturers of drugs, devices, or medical supplies to physicians and teaching hospitals.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $18.3K payment for?

This was a consulting payment of $18.3K from Merck & Co to Paul Turner, categorized as "Consulting Fee". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Paul Turner accept pharmaceutical money?

Yes, Paul Turner received this $18.3K payment from Merck & Co. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Paul Turner's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $18.3K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Infectious Disease?

To compare this payment against Infectious Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Infectious Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Paul Turner's relationship with Merck & Co?

The payment amount is substantial for a consulting fee. This $18.3K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Infectious Disease?

The payment was made in the near future (2025), suggesting a planned or ongoing relationship.

What should patients do after learning about this payment?

Patients should be aware that their doctors may receive payments from pharmaceutical companies for consulting, which helps advance medical knowledge.

What else should I know about this consulting payment?

The specific nature of the consulting is not detailed, leaving room for interpretation.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.